EUCTR2011-001093-26-GB进行中（未招募）1 期
A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients with Acute Exacerbations of Asthma - AZithromycin Against pLacebo in Exacerbations of Asthma (AZALEA)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 199
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients meeting all of the following criteria will be considered for admission to the study: • Adults, either sex, ages 18-55 years or age 56 to 65 with < 20 pack year smoking history or >65 with <5 pack year smoking history • Patients with a documented history of asthma for >6 consecutive months, and • Patients presenting within 24 hours (of initial presentation to medical care) with an acute deterioration in asthma control (increased wheeze, dyspnea and/or cough and/or reduced PEF) and requiring a course of oral steroids • Patients with a PEF or FEV1 less than 80% of predicted normal or patient’s best at presentation, at recruitment or in the time elapsed between presentation and recruitment • Patients must be able to complete diaries and quality of life questionnaires. • Patients must sign and date an informed consent prior to any study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Patients presenting with any of the following will not be included in the study: • Smokers aged 56-65 with a > or equal to 20 pack year history • Patients requiring immediate placement in ICU • Patients who used oral or systemic antibiotics within 28 days prior to enrolment • Patients with known impaired hepatic function (ALT/AST > 2 ULN) • Patients with significant lung disease (including COPD) other than asthma • Patients with = 10mg oral corticosteroid maintenance therapy • Patients requiring other antibiotic therapy • Patients who are receiving other medications or who have other disease conditions or infections that could interfere with the evaluation of drug efficacy or safety • Women who are breast-feeding or are pregnant, as demonstrated by a urine pregnancy test carried out before exposure to study medication or the start of any study procedure that could pose a risk to the foetus • Patients with suspected or known hypersensitivity to, or suspected serious adverse reaction to Azithromycin or any of the macrolide or ketolide class of antibiotics, erythromycin or to any excipients thereof • Patients who have received treatment with any other investigational drug within 1 month prior to study entry, or have such treatment planned for the study period during treatment and follow up phase • Patients with a concomitant condition (including clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease) making implementation of the protocol or interpretation of the study results difficult • Patients with mental conditions rendering them unable to understand the nature, scope, and possible consequences of the study. • Patients unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits. • No subject will be allowed to enrol in this study more than once.
研究者
相似试验
进行中（未招募）
1 期
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on DialysisTreatment of hyperphosphataemiaMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseEUCTR2007-003885-16-FRGenzyme Europe BV400
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary SyndromeCoronary Artery DiseaseMedDRA version: 9.1Level: PTClassification code 10011078Term: Coronary artery diseaseEUCTR2006-000296-15-BEEisai Limited600
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on DialysisTreatment of hyperphosphataemiaMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseEUCTR2007-003885-16-GRGenzyme Europe BV400
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not on DialysisTreatment of hyperphosphataemiaMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseEUCTR2007-003885-16-SEGenzyme Europe BV400
进行中（未招募）
1 期
A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 Months in Subjects Undergoing Bilateral Nerve-Sparing Radical Prostatectomy - LVIKErectile dysfunction following Bilateral Nerve-Sparing Radical ProstatectomyMedDRA version: 12.0 Level: LLT Classification code 10050756 Term: Radical prostatectomyMedDRA version: 12.0 Level: LLT Classification code 10061461 Term: Erectile dysfunctionEUCTR2009-011850-17-GBEli Lilly and Company Limited